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Abstract
Background: We assessed the relationship between physiologic parameters, computed tomography patterns, 6
minute walk distance (6MWD) and the distance-saturation product [DSP; defined as the product of the 6MWD and
the lowest oxygen saturation during the 6 minute walk test (6MWT)]. In addition, we investigated factors affecting
6MWD in patients with pulmonary sarcoidosis.
Methods: We performed a retrospective study of patient demographics, treatment, pulmonary function, 6MWT,
echocardiography and computed tomography results.
Results: Fifty nine patients were included in this study. Their mean+standard deviation age was 47.5 years + 12.5 years,
and 42 (71.2%) were female. Mean pulmonary function parameters for forced vital capacity (FVC), forced expiratory
volume in 1 second (FEV1) and total lung capacity (TLC) results, as percentages of predicted values, were 77.6 ± 22.2,
77.1 ± 22.8 and 78.7 ± 16.1, respectively. Comparison of the DSP with distance walked revealed a significant correlation
with factors underlying reduced 6MWD, including gender, pulmonary function indices, partial pressure of oxygen
(PaO2), and Borg dyspnea score. Other factors were significantly associated with DSP but not distance; these included
lung fibrosis (p = 0.02), pulmonary hypertension (p = 0.01) and systemic therapy (p = 0.04). Backward elimination
stepwise multiple regression analysis revealed that gender, and FEV1 were independent predictors of 6MWD, but FEV1
was more strongly related when DSP applied [DSP, R
2 = 0.53, p = 0.02; distance, R
2 = 0.45, p < 0.0001].
Conclusion: Our findings reveal that, compared to 6MWD alone, the DSP is correlated with a greater number of
factors associated with reduced 6MWT performance. Therefore, the DSP may be a useful indicator of functional
status in patients with sarcoidosis. Additional large-scale studies are warranted to validate our findings.
Background
Sarcoidosis is a multisystem disorder characterized by
noncaseating granulomas that most commonly affect the
lungs and lymph nodes. Despite extensive research, the
cause of sarcoidosis remains unknown. However, sub-
stantial evidence supports the hypothesis that sarcoidosis
stems from interactions among genetic and environmen-
tal factors, which would account for the significant het-
erogeneity in this disease across different ethnic groups.
Most patients with sarcoidosis experience spontaneous
remission or nonprogressing disease; however, as many
as one third of patients develop chronic progressive
disease [1]. Clinicians frequently find it difficult to man-
age sarcoidosis patients due to the significant variability
in disease manifestation, diverse organ involvement and
multiple non-specific symptoms. Furthermore, outcome
measures (e.g., pulmonary function indices, histopatho-
logic abnormalities and high-resolution computed tomo-
graphy findings) are often nonspecific or have limited
prognostic value [2-5].
Over the past decade, the 6 minute walk test (6MWT)
has become a popular tool to predict the prognoses of
patients with various pulmonary and non-pulmonary
diseases, including idiopathic pulmonary fibrosis (IPF),
chronic obstructive lung disease, pulmonary hyperten-
sion (PH), and chronic heart failure [6-9]. Among
patients with IPF, the 6MWT parameters of desatura-
tion [6] and distance [10] can discriminate between
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of the distance walked during the 6MWT (6MWD) and
oxygen saturation (SpO2) (i.e., the distance-saturation
product, or DSP) is a more reliable indicator of prog-
nosis than either parameter alone [11]. Because the
6 M W Ti ss i m p l e ,i n e x p e n s i v e ,r e p r o d u c i b l ea n dw e l l -
received by patients (as it mimics the effort required for
daily physical activity), it may be a useful tool to track
the progress of patients with sarcoidosis in an outpatient
setting. Several studies have used the 6MWT to evaluate
patients with sarcoidosis [12-15] and have found that
the majority of patients exhibit exercise intolerance,
which manifests as reduced walking distance. Recently,
we reported that several factors are associated with
shorter 6MWDs, including gender, percentage of pre-
dicted forced vital capacity (FVC), forced expiratory
volume in 1 second (FEV1), final Borg score and oxygen
saturation at the end of the 6MWT [15]. However, that
study included only a small number of patients from a
single center, which precluded the use of additional
tests to predict variables affecting the 6MWT para-
meters. Moreover, no previous study has examined the
relationship between chest CT patterns and 6MWT
parameters in patients with pulmonary sarcoidosis.
In the present retrospective study, we therefore sought
to determine the relationship between outcome mea-
sures of the 6MWT (i.e., distance and the DSP), physio-
logic parameters and CT patterns in a larger sample of
patients from three tertiary hospitals. Furthermore, we
tested the hypothesis that the DSP is more effective
than 6MWD for identifying variables involved in overall
functional status in patients with pulmonary sarcoidosis.
Methods
Study Population
Our study population consisted of 59 patients who were
diagnosed with pulmonary sarcoidosis, based on biopsy
results, between January 2002 and December 2008. Medi-
cal records of all patients attended an outpatient pulmon-
ary clinic at one of three study centers, specifically, King
Khalid University Hospital, King Abdulaziz Medical City,
and Riyadh Military Hospital, in Riyadh, Saudi Arabia
were reviewed. The study protocol was approved by the
Ethics Committee of each hospital and informed patients
consent was waived. Some of the participants in the cur-
rent investigation were included in our previous studies
of Arab patients diagnosed with pulmonary sarcoidosis
[15,16]. Sarcoidosis was diagnosed based on the most
recent criteria published by the American Thoracic
Society (ATS), the European Respiratory Society (ERS)
and the World Association of Sarcoidosis and Other
Granulomatous Disorders (WASOG) [17]. Data included
patient demographics, treatment, pulmonary function,
6MWT, CT and echocardiography findings. The CT
reports were collected from medical records and were
examined for the following recognized patterns [18]:
(1) ground-glass opacity; (2) linear opacity, including
interlobular septal lines and interstitial thickening; and
(3) features indicating scarring and fibrosis (grouped
together), including traction bronchiectasis, honeycomb-
ing, cysts, or volume loss. Treatment regimens consisted
of none (no treatment), corticosteroids, corticosteroids
plus azathioprine, or corticosteroids plus methotrexate.
Treatment decisions were based on individual physician
opinions.
Measurements
FVC, FEV1 and total lung capacity (TLC) values (Erich
Jaeger Masterscreen PFT, GmbH D-97201Hoechberg,
Germany) were expressed as percentages of predicted
values according to gender, weight and age. Measure-
ments were performed according to the recommenda-
tions of the ATS [19]. The predicted values currently
used were those of Quanjer and colleagues [20]. Arterial
blood gas values (Rapid lab 865; Bayer, Plymouth, UK)
were obtained on the same day as the 6MWT was per-
formed. Sampling included partial pressure of oxygen
(PaO2), partial pressure of carbon dioxide (PaCO2)a n d
oxygen saturation (SaO2) measurements.
The 6MWT was conducted in accordance with ATS
guidelines [21]. All patients exhibited resting oxygen
saturation (SpO2) > 88% at the beginning of the walk
test. Heart rate, blood pressure, oxygen saturation and
Borg dyspnea index [22] were recorded at the beginning
and end of the 6 minute walk. The total distance walked
(in meters) was documented at the end of the test.
The DSP was defined by Lettieri and colleagues [11]
as the product of the 6MWD and the lowest room air
SpO2. For example, if the total distance is 300 m and
the lowest SpO2 is 88% at the end of the 6MWT, the
DSP value would be 264 m% (i.e., 300 × 0.88).
Pulmonary hypertension (PH) was diagnosed based on
Doppler echocardiography. Specifically, PH was defined
as an estimated right ventricular systolic pressure of
> 40 mm Hg in the absence of significant left heart dys-
function, according to criteria established by a World
Health Organization symposium on primary PH [23].
Statistical Analysis
Descriptive statistics [i.e., means, standard deviations,
percentages, and 95% confidence interval (CI)] were
applied to summarize the continuous and categorical
variables. The relationship between two continuous vari-
ables was determined by measuring the Pearson’s corre-
lation coefficient. Student’s t-test for independent
samples was used to compare the mean values of con-
tinuous variables. The chi-square test was applied to
compare the proportion of categorical study variables
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elimination stepwise multiple regression model for dis-
tance and DSP was developed using variables found to
be significant (p < 0.05) in the univariate analysis. Statis-
tical Software Package for Social Sciences (SPSS version
13.0; SPSS, Inc; Chicago, Illinois, USA), and PASW ver-
sion 18.0 were used to analyze the data.
Results
Among the 59 patients with sarcoidosis analyzed in the
present study, 42 (71.2%) were female. The mean age at
diagnosis was 47.5 years (range: 19 years to 83 years).
Aberrations in FVC results (< 80% of predicted values)
were observed in 30 patients (50.8%). The mean ± stan-
dard deviation (SD) for FVC, FEV1 and TLC results, as
percentages of predicted values, were 77.6 ± 22.2, 77.1 ±
22.8 and 78.7 ± 16.1, respectively. The 6MWT results are
summarized in Table 1. The mean 6MWD for the entire
cohort was 349 m + 72 m (range: 163 m to 500 m).
Thirteen patients (22.0%) achieved 6MWDs > 400 m, 34
patients (57.6%) walked 300 m to 400 m and 12 patients
(20.3%) walked < 300 m. On average, females walked a
significantly shorter distance than males. The differences
are summarized in Table 2 and Table 3. The correlation
between factors associated with 6MWD and DSP are
shown in Table 4 and Table 5, according to simple
regression analysis. 6MWD and DSP were positively
correlated with absolute values of FVC, FEV1 and TLC.
However, DSP was more significantly correlated with
these values.
The CT findings revealed ground-glass opacity in
32.2% of the patients, linear opacity in 27.1% of the
patients and scarring and fibrosis in 40.6% of the
patients. Comparison of patients with and without
ground glass opacity revealed a shorter walking distance
for the former; however, no significant differences were
observed across groups [DSP (m%): 299.2 + 71.8 and
399.3 + 76.0, respectively; p = 0.08; distance (m): 337 +
72.7 and 363 + 70.7, respectively; p =0 . 2 4 ] .N o
statistical differences in 6MWD were noted between
patients with and without linear opacity [DSP (m%):
301.5 + 68.4 and 332.3 + 78.8, respectively; p =0 . 2 1 ;
distance (m): 331.8 + 67.8 and 362.2 + 73.0, respectively;
p = 0.19]. A significant difference was noted for DSP,
but not for 6MWD, when patients with lung fibrosis
were compared with those without fibrosis. The differ-
ences are summarized in Table 2 and Table 3.
Doppler echocardiography was performed in 46
patients (78%). Of those patients, pulmonary artery sys-
tolic pressure > 40 mm Hg was documented in 12
patients (23%). Differences in mean DSP values were
greater than those in 6MWDw h e np a t i e n t sw i t hP H
Table 1 Outcome of six minutes walk test
Variables Mean (SD)
Initial heart rate, b/m 93.0 (15.6)
Final heart rate, b/m 109.2 (19.2)
Initial Borg score 0.35 (0.7)
Final Borg score 2.4 (2.1)
Initial SpO2, % 95.5 (2.4)
Lowest SpO2, % 91.4 (7.3)
6MWD, m 349.0 (72)
DSP, m% 320.0 (75)
SD: standard deviation; b/m: beats per minute;
SpO2: oxygen saturation by pulse oximetry;
6MWD: 6-min walk distance; DSP: distance saturation product
Table 2 Univariate analysis: Comparison of mean value of
distance with categorical variables
Variables Distance
Mean (SD)
t-value p-value 95% CI
Gender
Female 324.1 (65.6) 5.0 < 0.0001 513, 119.2
Male 409.4 (44.4)
Pulmonary hypertension
Yes 313.2 (63.1) 1.85 0.07 -3.9, 90.3
No 356.5 (71.6)
Treatment
Yes 343.9 (70.9) 1.27 0.21 -16.7, 75.1
No 373.1 (71.8)
Scarring and fibrosis
Yes 333.7 (68.8) 1.89 0.06 -2.7, 83.9
No 374.3 (71.0)
Table 3 Univariate analysis: Comparison of mean value of
DSP with categorical variables
Variables Distance
Mean (SD)
t-value p-value 95% CI
Gender
Female 300.8 (70.6) 3.46 < 0.001 28.2, 105.3
Male 367.6 (62.8)
Pulmonary hypertension
Yes 268.03 (66.1) 2.55 0.01 12.7, 108.3
No 328.5 (72.1)
Treatment
Yes 311.3 (72.8) 2.04 0.04 0.83, 94.6
No 359.0 (71.9)
Scarring and fibrosis
Yes 297.9 (70.2) 2.42 0.02 8.8, 98.0
No 3513 (74.2)
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are summarized in Table 2 and Table 3.
We assessed the effects of treatment on the 6MWD
and found that 47 patients (79.6%) were administered
corticosteroids alone or in combination with immuno-
suppressive therapy, while 12 patients (20.3%) did not
receive any therapy. Patients receiving therapy achieved
shorter 6MWDs than those not receiving treatment. In
these cases, a significant difference was noted for DSP,
but not distance shown in Table 2 and Table 3.
Significant variables identified by univariate analysis were
assessed in a stepwise multiple regression model, using
backward elimination method. Separate models were
developed for distance and for DSP. The models included
gender, FEV1,F V C ,T L C ,f i n a lB o r gs c o r e ,l o w e s tS p O 2
(distance model only), PaO2, presence of CT fibrosis, treat-
ment status and presence of PH. In the distance model,
gender and absolute value of FEV1 were identified as signif-
icant independent variables. Whereas, in the DSP model
FEV1 w a sm o r es t r o n g l yr e l a t e d .R e s u l t sa r es h o w ni n
Table 6, and Table 7.
Discussion
Our results demonstrate that exercise intolerance among
patients with pulmonary sarcoidosis manifests as shorter
distances walked during the 6MWT. We have identified
several factors that contribute to reductions in 6MWD,
including gender, pulmonary function parameters, dys-
pnea score, and PaO2. Furthermore, DSP was more
significantly correlated with physiologic indices than was
6MWD. Our findings demonstrated that DSP, but not
distance, was significantly associated with CT fibrosis,
systemic therapy and PH.
Traditionally, pulmonary function tests (PFTs) have
been used in the management of individuals with pul-
monary sarcoidosis to identify patients with pulmonary
involvement and to follow the course of the disease.
However, the predictive power of these tests is limited
[24,25]. Furthermore, the correlation of dyspnea with
PFTs has produced discordant results among patients
with sarcoidosis [26,27], suggesting that additional
methods for the evaluation of functional status are
needed. Consistent with previous studies, our data
demonstrate that FVC, FEV1 and TLC are significantly
correlated with 6MWD [12,15]. However, DSP showed a
much higher correlation with pulmonary function para-
meters than did 6MWD alone.
Previous studies that used the Borg score to measure
the perception of breathlessness during exertion have
yielded inconsistent results. Mador and colleagues [28]
found that Borg ratings of dyspnea among patients with
chronic obstructive pulmonary disease were highly vari-
able at submaximal levels of exercise compared with
maximal levels of exercise, whereas Mack and associates
[29] noted a better correlation when patients performed
a walking test rather than a maximal exercise test. We
found a significant inverse correlation between Borg
score and 6MWD, consistentw i t hp r e v i o u ss t u d i e s
Table 4 Simple regression analysis: Relationship between distance and quantitative study variables
Outcome
Variables
Independent
Variables
Unstandarized
Coefficient
Standarized
Coefficient
Beta
t-value p-value R
2
B S. Error
DISTANCE FEV1, L 43.81 9.44 0.52 4.64 < 0.0001 0.271
FVC, L 37.58 8.29 0.51 4.53 < 0.0001 0.262
TLC, L 25.32 8.26 0.39 3.1 0.003 0.158
Final Borg score -10.56 4.62 -0.35 -2.3 0.028 0.121
PaO2 mmHg 2.32 0.79 0.39 2.92 0.005 0.154
Lowest SpO2, % 1.85 1.26 0.19 1.47 0.15 0.036
FEV1: Forced expiratory volume in 1 second, FVC: Forced vital capacity;
TLC: Total lung capacity; PaO2: Partial pressure or oxygen; SpO2: oxygen saturation by pulse oximetry.
Table 5 Simple regression analysis: Relationship between DSP and quantitative variables
Outcome
Variables
Independent
Variables
Unstandarized
Coefficient
Standarized
Coefficient
Beta
t-value p-value R
2
B S. Error
DSP FEV1, L 52.1 9.3 0.59 5.61 < 0.0001 0.352
FVC, L 44.8 8.1 0.58 5.49 < 0.0001 0.342
TLC, L 31.2 8.0 0.48 3.90 < 0.0001 0.233
Final Borg score -14.8 4.7 -0.45 -3.12 0.003 0.205
PaO2 mmHg 2.87 0.82 0.45 3.49 0.001 0.206
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noted for DSP than for distance. Although the lungs are
the most commonly affected tissues in patients with sar-
coidosis, exercise intolerance can also be attributed to
other factors such as cardiac involvement and skeletal
muscle weakness.
The presence of PH was recently identified as an
important factor affecting the survival of patients with
sarcoidosis [24,30,31]. In the present study, 12 patients
with PH were identified. We observed a reduction in
walking distance among the patients with PH, consistent
with previous reports [12,32]. A statistically significant
difference was noted for DSP, but not distance, when
patients with PH were compared with those without
PH. Many factors (e.g., age, height, weight and effort)
may have major effects on 6MWD, which may explain
why we did not identify any statistically significant dif-
ferences in walking distance when we compared patients
with and without PH. Bourbonnais and Samavati [32]
reported that the level of oxygen saturation at 6 minutes
was better than walking distance at predicting the pre-
sence of PH in patients with sarcoidosis. However, the
purpose of that study was to identify variables that
could predict the presence of sarcoidosis-associated PH,
whereas the present study was designed to correlate
6MWT outcome measures (i.e., distance and DSP) with
various physiologic parameters, including the presence
of PH. Additional large-scale studies are warranted to
explore the value of DSP as a screening tool to identify
PH in patients with sarcoidosis.
Skeletal muscle weakness has a significant impact on
exercise tolerance in patients with sarcoidosis [14]. Fac-
tors that play a role in the development of muscle weak-
ness include myopathy, corticosteroid therapy, fatigue
and physical deconditioning. Patients receiving corticos-
teroid therapy in our study achieved shorter 6MWDs
than did those not receiving such therapy; interestingly,
this difference was significant for DSP but not 6MWD.
Although Baughman and Colleagues [12] noted signifi-
cant differences in 6MWD between patients who took
corticosteroids and those who did not, Spruit and associ-
ates [14] found no difference in muscle force or 6MWD
between patients taking corticosteroids and those not
receiving such treatment. This discrepancy may reflect
the marked heterogeneity in disease progression, dura-
tion of corticosteroid use, effects associated with race and
ethnicity, as well as extrapulmonary organ involvement,
fatigue, or physical deconditioning. Thus, future studies
are needed to explore the possible causes of skeletal mus-
cle weakness among patients with sarcoidosis.
While CT and high-resolution CT play a pivotal diag-
nostic role in the evaluation of diffuse interstitial lung
disease, including sarcoidosis, routine CT scanning is
not advocated in the management of sarcoidosis, except
in patients with normal or atypical chest radiography or
specific complications such pulmonary fibrosis, bronch-
iectasis, aspergilloma or malignancy [17,33]. Several stu-
dies have correlated CT patterns with pulmonary
function tests [2-4] and CT findings with pathological
abnormalities [5,34,35] among patients with pulmonary
sarcoidosis. However, CT patterns have never before
been correlated with 6MWT results. In the present
study, 40.6% of the patients exhibited CT patterns indi-
cative of lung fibrosis. Although patients with lung
fibrosis tended to walk shorter distances, the difference
in 6MWD between groups was not statistically signifi-
cant. By contrast, the DSP value did differ significantly
between patients with and without lung fibrosis, sug-
gesting that DSP has the potential to identify a subset of
patients with pulmonary fibrosis and therefore may pro-
vide indirect information about global functional status.
Discordance in the outcomes of patients with ground
glass attenuation has been observed in several studies
[3,4,36]. Furthermore, attempts to correlate ground glass
Table 6 Stepwise regression analysis (backward elimination method): Relationship between distance and study
(categorical and quantitative) variables
Outcome
Variables
Independent
Variables
Unstandarized
Coefficient
Standarized
Coefficient
Beta
t-value p-value 95%CI R
2
B S. Error
DISTANCE Gender -43.5 16.7 -0.35 -2.56 0.016 -78.3, -8.7 0.45
FEV1 46.1 11.7 0.54 3.95 < 0.0001 22.2, 69.9
Table 7 Stepwise regression analysis (backward elimination method): Relationship between DSP and study
(categorical and quantitative) variables
Outcome Variables Indepndent Variables Unstanardized Coefficients Standardized Coefficients
Beta
t -value p-value 95% CI R
2
B S. Error
DSP FEV1 43.4 17.3 0.489 2.5 0.02 6.4, 80.4 0.53
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reports of granulomatous infiltration or fibrosis [34,35].
We noted a trend toward statistical significance when
DSP was used to assess patients with and without
ground glass opacity. Future studies should use DSP to
correlate the reversibility of ground glass opacity with
6MWT results in response to therapy.
The present study found that female gender was asso-
ciated with a significant reduction in 6MWD. This effect
persists when multiple regression analysis was applied
for the distance but not for DSP. Furthermore, we iden-
tified FEV1 as predictive factor among our cohort. Our
results conflict with a previous report by Baughman and
colleagues [12], who found that FVC, oxygen saturation
with exercise and self-reported respiratory health were
independent variables associated with 6MWD.
Exercise among patients with sarcoidosis requires a
global and integrated response of the cardiovascular,
respiratory, neuromuscular and metabolic systems,
which might explain why FEV1 accounted for 53% of
the changes in DSP and 45% of the changes in 6MWD.
These results indicate that factors other than lung func-
tion may have a significant effect on 6MWD. Baughman
and colleagues [12] found that activity scores on the St.
G e o r g eR e s p i r a t o r yQ u e s t i o n n a i r ew e r em o r ee f f e c t i v e
than FVC at predicting 6MWD results. In another
study, Kabitz and colleagues [13] found that inspiratory
muscle strength was more effective than FVC or resting
PaO2 at predicting 6MWD results. However, neither of
these studies determined the predictor variable that
accounts for total variance (i.e., r
2) for 6MWD, thus pre-
cluding meaningful comparison with our data.
Both 6MWD and desaturation during 6MWT are
valuable tools for predicting functional capacity and
mortality in various pulmonary and non-pulmonary dis-
eases [6-9]. Thus, use of the outcome measure, DSP, in
conjunction with 6MWT and other tests may help with
the management of patients with sarcoidosis by provid-
ing additional information about functional status. In
addition, DSP may serve as a useful assessment tool for
monitoring patient responses to therapy.
The present study had several limitations. First, our
work is a retrospective review wherein clinical informa-
tion was obtained from hospital records. Our clinical
setting is a tertiary-care hospital where selection bias
toward patients with more advanced disease is inevita-
ble. Finally, small number of patients in our cohort rela-
tive to the studied variables mandates external
validation of our prediction model before it can be used
in clinical practice.
Conclusions
Several factors were associated with a reduction in
6MWD among patients with sarcoidosis. When DSP was
used instead of 6MWD, we identified several additional
factors associated with reductions in 6MWT perfor-
mance, including CT fibrosis, systemic therapy and PH.
Stepwise multiple regression analysis revealed that FEV1
was an independent predictor of 6MWD and was a sig-
nificantly better predictor of DSP than of 6MWD. This
study is the first to demonstrate a correlation between
6MWT results and CT fibrosis, and suggests that DSP is
a potential indicator of functional status in patients with
sarcoidosis.
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